Shares of MediciNova Inc. (MNOV) surged more than 41% on Thursday, following receipt of FDA’s Fast Track designation for the company’s phase II-ready compound – MN-001 – for the treatment of patients with nonalcoholic steatohepatitis with fibrosis.
Forex – financial instrument.Forex news
Shares of MediciNova Inc. (MNOV) surged more than 41% on Thursday, following receipt of FDA’s Fast Track designation for the company’s phase II-ready compound – MN-001 – for the treatment of patients with nonalcoholic steatohepatitis with fibrosis.